Paper309306
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
English AR and 4 others. Antimicrob Agents Chemother, 1978. Cited by 379 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Papers, record 309306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/309306
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Thiazoles | Major topic |
| beta-Lactamase Inhibitors | Major topic |
| Ampicillin | |
| Drug Therapy, Combination | |
| beta-Lactams |
Source PubMed
References5
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14,480,578 | Micro-iodometric assay for penicillinase. | Biochem J | 1962 | https://conductscience.org/library/papers/14480578 | PubMed |
| 2 | 879,738 | Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. | Antimicrob Agents Chemother | 1977 | https://conductscience.org/library/papers/879738 | PubMed |
| 3 | 5,195,741 | Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins. | Antimicrob Agents Chemother (Bethesda) | 1968 | https://conductscience.org/library/papers/5195741 | PubMed |
| 4 | 783,110 | The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics. | J Antimicrob Chemother | 1976 | https://conductscience.org/library/papers/783110 | PubMed |
| 5 | 950,324 | Naturally-occurring beta-lactamase inhibitors with antibacterial activity. | J Antibiot (Tokyo) | 1976 | https://conductscience.org/library/papers/950324 | PubMed |
Cited by99
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 379 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,239,032 | Cooperative antibiotic response in coupled biofilm and planktonic E. faecalis communities. | bioRxiv | 2026 | https://conductscience.org/library/papers/42239032 | PubMed |
| 41,907,167 | Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii. | Curr Res Microb Sci | 2026 | https://conductscience.org/library/papers/41907167 | PubMed |
| 41,113,112 | Structural insights into the activity of carbapenemases: understanding the mechanism of action of current inhibitors and informing the design of new carbapenem adjuvants. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/41113112 | PubMed |
| 40,952,390 | Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40952390 | PubMed |
| 40,734,664 | Amphiphilic nebramine analogs synergize with β-lactam/β-lactamase inhibitor combinations, including cefepime-taniborbactam and meropenem-xeruborbactam against metallo-β-lactamase-carrying Pseudomonas aeruginosa. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/40734664 | PubMed |
| 38,188,094 | Mechanism-Based Enzyme Inactivation Using an Allyl Sulfoxide-Allyl Sulfenate Ester Rearrangement1. | J Am Chem Soc | 1980 | https://conductscience.org/library/papers/38188094 | PubMed |
| 37,125,470 | Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/37125470 | PubMed |
| 35,486,701 | Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/35486701 | PubMed |
| 34,250,791 | The G132S Mutation Enhances the Resistance of Mycobacterium tuberculosis β-Lactamase against Sulbactam. | Biochemistry | 2021 | https://conductscience.org/library/papers/34250791 | PubMed |
| 34,129,337 | Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design. | Chem Rev | 2021 | https://conductscience.org/library/papers/34129337 | PubMed |
| 33,199,391 | Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33199391 | PubMed |
| 32,591,801 | Discovery and characterization of New Delhi metallo-β-lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/32591801 | PubMed |
| 31,150,547 | Antibiotic resistance breakers: current approaches and future directions. | FEMS Microbiol Rev | 2019 | https://conductscience.org/library/papers/31150547 | PubMed |
| 30,837,684 | Interplay between β-lactamases and new β-lactamase inhibitors. | Nat Rev Microbiol | 2019 | https://conductscience.org/library/papers/30837684 | PubMed |
| 30,061,509 | Tackling the Antibiotic Resistance Caused by Class A β-Lactamases through the Use of β-Lactamase Inhibitory Protein. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30061509 | PubMed |
| 27,329,032 | β-Lactams and β-Lactamase Inhibitors: An Overview. | Cold Spring Harb Perspect Med | 2016 | https://conductscience.org/library/papers/27329032 | PubMed |
| 27,000,559 | Targeting Antibiotic Resistance. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/27000559 | PubMed |
| 24,272,507 | The molecular basis for the mode of action of Beta-lactam antibiotics and mechanisms of resistance. | Pharm Res | 1985 | https://conductscience.org/library/papers/24272507 | PubMed |
| 24,100,499 | Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/24100499 | PubMed |
| 23,547,944 | Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase. | Theor Biol Med Model | 2013 | https://conductscience.org/library/papers/23547944 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/309306
GET https://conductscience.org/api/papers/v1/309306/cited_by?page=2